Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM548TK)

Drug Name

KD025 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Psoriasis vulgaris	EA90	Phase 2	[1]
Rheumatoid arthritis	FA20	Phase 2	[2]
Psoriatic arthritis	FA21	Phase 1	[3]
Scleroderma	4A42	Phase 1	[3]
Systemic lupus erythematosus	4A40.0	Phase 1	[3]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Rho-associated protein kinase 2 (ROCK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
INS-117548	DMA46DO	Glaucoma/ocular hypertension	9C61	Phase 1	[5]
GSK269962A	DM5I2HL	Inflammation	1A00-CA43.1	Clinical trial	[6]
PMID28048944-Compound-19	DMPT3V9	N. A.	N. A.	Patented	[7]
PMID28048944-Compound-3	DM1BN74	N. A.	N. A.	Patented	[7]
PMID28048944-Compound-7	DMXZ368	N. A.	N. A.	Patented	[7]
PMID28048944-Compound-4	DMJAUWG	N. A.	N. A.	Patented	[7]
PMID28048944-Compound-5	DMAB987	N. A.	N. A.	Patented	[7]
PMID28048944-Compound-6	DM5RCBV	N. A.	N. A.	Patented	[7]
PMID28048944-Compound-2	DM9ZXOP	N. A.	N. A.	Patented	[7]
Tricyclic compound 7	DME84S5	N. A.	N. A.	Patented	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Rho-associated protein kinase 2 (ROCK2)	TTGWKQJ	ROCK2_HUMAN	Inhibitor	[4]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT02317627) Study of of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-Line Therapy. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814-9.
5	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
6	Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.
7	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.